China’s FDA approves Simcere’s rheumatoid arthritis drug

Earlier on Thursday, Simcere Pharmaceutical Group announced that China’s State Food and Drug Administration has granted marketing approval for Iremod, a drug intended to treat rheumatoid arthritis. Endu and Sinofuan are amongst the cancer treatments manufactured by Simcere along with other drugs including branded generics and over-the-counter products.
In afternoon trading, American depositary shares of the Chinese drugmaker jumped 9 cents to $8.60.